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ABSTRACT : Fifty-six bronchoscopies were carried out for the diagnosis of 
pulmonary diseases in 50 immunocompromised patients with various underlying dis-
eases. In 30 of these patients, bronchoscopy provided useful findings. The diagnostic 
sensitivities (positive/procedures) for transbronchial lung biopsy bronchoalveolar 
lavage, aspiration of intra-bronchial sputum and brushing were 55.1%, 29.4%, 8.3% 
and 0%, respectively. Overall diagnostic sensitivity was higher for non-infectious dis-
eases than for infectious ones. Also, there was a tendency for the diagnostic sensitiv-
ity to be higher in cases whose pulmonary infiltrates were extensive. In two samples 
of lavage fluid positive for the isolation of cytomegalovirus, the virus was not signif-
icant etiologically. Complications from bronchoscopy occurred in nine patients, but 
were not serious. However, no prolonged patient survival was noted with the use of 
diagnostic bronchoscopy. We consider that bronchoscopy is a safe method for the 
diagnosis of pulmonary diseases in immunocompromised patients, but that further 
studies are required in order to confirm the clinical significance of this procedure.
       INTRODUCTION 
 Fiberoptic bronchoscopy has been increasing-
ly utilized for the diagnosis of various pulmo-
nary diseases, and has made diagnosis reliable 
and accurate. In the late 1970s, bronchoalveo-
lar lavage using bronchoscopy was introduced', 
allowing the analysis of lung cells, and broncho-
scopic laser therapy was also developed. Thus, 
bronchoscopy has brought about remarkable
progress in the diagnosis and treatment of pul-
monary diseases. The number of diseases for 
which bronchoscopy is indicated has also in-
creased. Many investigators have reported the 
usefulness of bronchoscopy in the diagnosis of 
pulmonary complications in immunocompro-
mised patients such as those with malignant 
disease, organ transplant recipients 1-7) or those 
with acquired immunodeficiency syndrome 
(AIDS).8-12) 
 We have diagnosed pulmonary complications
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using bronchoscopy in 50 immunocompromised 
patients with various underlying diseases, and 
have studied the clinical significance of diag-
nostic bronchoscopy. Our findings are reported 
in the present paper. 
        MATERIALS 
 During the period from March 1977 to June 
1986, 50 immunocompromised patients under-
went bronchoscopy at the Second Department 
of Internal Medicine, Nagasaki University Hos-
pital for the diagnosis of pulmonary diseases. 
They comprised 31 men and 19 women ranging 
in age from 19 to 78 years, with a mean age of 
52 years. 
 Among the underlying diseases in these 50 
patients, hematologic malignancy was the most 
common condition, and about half of such 
patients had malignant lymphoma. Seven pa-
tients had been treated with steroids ; these 
included f our patients with nephrotic syndrome, 
one with sarcoidosis, one with aplastic anemia 
and one with autoimmune hemolytic anemia. 
Three patients had solid malignant tumors ; 
one case each of lung cancer, bladder cancer and 
breast cancer. The two other patients were a 
renal transplant recipient and one with myelo-
dysplasia (Table 1).
Table 1. Underlying Diseases of 50 Immunocom-
       promised Patients 
Underlying disease No. of patients (%) 
Hematologic malignancy 38(76) 
  non-Hodgkin's 19 
            lymphoma 
  Hodgkin's disease 3 
  Leukemia 15 
  Multiple myeloma 1 
Disease treated 7(14) 
           with steroids 
Solid malignant tumor 3 ( 6) 
Renal transplant 1 ( 2) 
Myelodysplasia 1 ( 2) 
   Total 50000)
 The radiographic patterns of pulmonary in-
filtrates are shown in Table 2. In 38 patients, 
arterial blood gases without supplemental oxy-
gen were determined before bronchoscopy. The 
relationship between the radiographic patterns
and arterial oxygen tension (PaO2) is shown in 
Table 2. 
Table 2. Radiographic patterns of Pulmonary In-
       filtrates and Arterial Oxygen Tension 
       (Path) 
  Pattern No. (%) Hypoxemic* Non-
                              hypoxemic* 
Bilateral 22 (44) 13 6 
   diffuse 
Unilateral 16 (32) 2 8 
  localized 
Bilateral 12 (24) 3 6 
 localized 
  Total 50 (100) 18' 20' 
*Hypoxemic : Pat h < 60 torr, Non-hypoxemic : 
Pa02 > 60 torr 
'In 38 patients , Path before bronchoscopy was 
measured without supplemental oxygen.
         METHODS 
 All patients were given atropine sulfate, 
pentazocine, and 4% lidocaine topical anesthes 
is before the bronchoscopy. The bronchoscope 
(Olympus BF-B2, 4B2, 1TR, 2TR) was passed 
transorally into the trachea. Bronchoscopy was 
done under fluoroscopy in principle and hypo-
xemic patients underwent bronchoscopy with 
supplemental oxygen. Transbronchial lung biop-
sy (TBLB ), aspiration of intra-bronchial 
sputum using a polyethylene tube (Asp), bron-
choalveolar lavage (BAL) or brushing was 
selected. For BAL, the bronchoscope was wedg-
ed into an involved subsegment, and 60 to 100 
ml of normal saline was instilled in 30- to 50-
ml aliquots, each aliquot then being aspirated 
manually. Chest radiographs were taken rou-
tinely on the day after BAL and changes in 
infiltrates were examined. In some patients, 
arterial blood gases were determined just be-
fore and after bronchoscopy. 
 Hematoxylin and eosin, silver methenamine 
and Ziehl-Neelsen staining were carried out on 
the transbronchial biopsy specimens. The aspi-
rated sputum, lavage fluids and brushings were 
sent for bacterial, fungal and mycobacterial 
staining and culture. The lavage fluids were 
pooled and centrifuged for five minutes at 1,500 
rpm. The sediment was smeared and stained 
with Papanicolaou, silver methenamine and
toluidine blue 0 stains. Isolation of cytomegalo-
virus (CMV) from five samples of lavage 
fluid was done. 
 A final diagnosis of pulmonary disease was 
made on the basis of bronchoscopic and autopsy 
findings and the clinical course including the 
response to specific treatment. Finally, a spe-
cific pulmonary disease was identified in 44 of 
the 50 patients, and was not identified in six 
patients. The specific diseases in these 44 pa-
tients were classified into infectious diseases 
(in 26 ), non-infectious diseases (in 15) and 
mixed-type diseases (in 3).
          RESULTS 
 Fifty-six bronchoscopies were done in 50 pa-
tients (Table 3). 
Table 3. Bronchoscopic Procedures Performed 
       in 50 Patients 
      Procedure No. of procedures 
  TBLB alone 22 
  TBLB+Asp 15 
  TBLB+BAL 6 
  TBLB+BAL+Asp 6 
  BAL alone 4 
  BAL+Asp 1 
  Asp alone 1 
  Asp+Brush 1 
       Total 56
TBLB = transbronchial lung biopsy; BAL = 
bronchoalveolar lavage ; Asp = aspiration of 
intra-bronchial sputum ; Brush = brushing.
TBLB, BAL, Asp and brushing were performed 
alone or in combination. TBLB was performed 
in 45 patients, Asp in 24, BAL in 17 and brush-
ing in one. A specific pulmonary disease was 
unequivocally diagnosed in 20 patients (40%) 
by bronchoscopy alone, and was suspected in 10 
patients (20%) on the basis of bronchoscopic 
and clinical findings. In these 10 patients, a 
specific form of treatment after bronchoscopy 
was effective, and the usefulness of broncho-
scopy for the diagnosis of pulmonary diseases 
was demonstrated. As a whole, bronchoscopy 
was useful in 30 patients (60 %) (Table 4 ). 
In two samples of lavage fluid positive for 
isolation of CMV, the isolated virus was not
Table 4. Diagnostic Findings on Bronchoscopy 
      Etiologic Diagnosis No. of 
                          patients (%) 
Definitive 20 (40) 
  Pneumocystis carinii 6*
  Tuberculosis 3 
  Cryptococcus 3 
  Aspergillus 1 
  (Cytomegalovirus infection 2) 
  Lymphoma 3 
  Leukemia 2 
  Metastatic calcification 1 
  Pumonary ossification 1 
Not definitive, clinically useful 10 (20) 
  Pneumonia 5 
  Drug-induced pneumonitis 3 
  Hypersensitivity pneumonitis 1 
  Lymphoma 1 
         Total 30/50(60)
In one of these, cytomegalovirus inclusion 
bodies were seen in the lavage fluids. 
Cytomegalovirus'was isolated by bronchoalve-
olar lavage, but was not significant etiological-
ly. These patients were excluded. 
All pulmonary infiltrates were localized, and 
disappeared without any treatment or antibiot-
ics.
;ignif icant etiologically. Theref ore, CMV was 
iot included among the cases with positive 
)ronchoscopic findings. Histopathological find-
ngs in five cases of pneumonia showed infiltra-
tion of inflammatory cells and intra-alveolar 
)rganization. These five pulmonary infiltrates 
were localized and disappeared without any 
,treatment or antibiotics. All positive findings, 
except for three cases of Pneumocystis carinii 
pneumonia diagnosed by BAL alone, were ob-
tained by TBLB alone or by TBLB combined 
with other procedures. 
 The diagnostic sensitivities for TBLB, BAL 
and Asp were 55.1%, 29.4% and 8.3%, respec-
tively. All five positive samples of lavage fluid 
contained Pneumocystis carinii, l) and cytomeg-
alovirus inclusion bodies were seen simultane-
ously in one of them. Two positive Asp samples 
contained tubercule bacilli and Staphylococcus 
aureus. The diagnostic sensitivities of broncho-
scopy for infectious and non-infectious disease 
were 18/26 (69.2%) and 12/15 (80%), indicat-
ing a slightly higher rate for non-infectious 
disease. The diagnostic sensitivity for
radiographic patterns was 68.2% for bilateral 
diffuse infiltrates, which was the highest, 66.7 
% for bilateral local infiltrates and 43.8% for 
unilateral local infiltrates (Table 5 ). Thus, 
there was a tendency for the diagnostic sensi-
tivity of bronchoscopy to be higher'when the 
pulmonary infiltrate was more extensive.
Table 5. Diagnostic Sensitivity of Bronchoscopy 
                       Sensitivity (%) 
 Procedure* 
   Transbronchial biopsy , 27/49 (55.1) 
   Bronchoalveolar lavage 5/17 (29.4) 
   Aspiration of sputum 2/24 ( 8.3) 
  Brush 0/ 1 ( 0) 
 Disease Category 
   Infectious disease 18/26 (69.2) 
   Non-infectious disease 12/15 (80.0) 
 Radiographic Pattern 
   Bilateral diffuse 15/22 (68.2) 
   Unilateral localized 7/16 (43.8) 
   Bilateral localized 8/12 (66.7) 
* Sensitivity = positive/procedures (%) 
 Sensitivity = positive/patients (%) 
 Two patients, in which cytomegalovirus was 
 isolated in the lavage fluids, were excluded. 
 The effect of diagnostic bronchoscopy on 
patient survival was examined retrospectively. 
However, no prolonged survival was noted with 
this technique (Table 6). 
Table 6. Effect of Bronchoscopy on Patient Sur-
        vival 
                Results of Bronchoscopy 
 Prognosis 
             Diagnostic Non-diagnostic 
  Survived 15 (50) 10 (50) 
 Died 15 (50) 10 (50) 
  Total 30 (100%) 20 (100%)
 Complications from bronchoscopy occurred 
in nine patients (18%) ; three with pneumotho-
rax and six showing a transient increase in 
temperature. None of the cases of pneumotho-
rax required tube drainage. The cases of fever 
occurred in five BAL patients and in one who 
underwent a combined procedure of TBLB and 
Asp. The infiltrates showed no worsening on 
radiographs taken on the day after broncho-
scopy. Moreover, no other serious complica-
tions occurred.
        DISCUSSION 
 Pulmonary complications occur frequently in 
the immunocompromised host, and the mortal-
ity is high when the infiltrates are extensive.13) 
Therefore, it is necessary to find and treat such 
cases as early as possible. In parallel with 
changes in underlying diseases, various pulmo-
nary complications are encountered, and dis-
crimination among them is often difficult."') 
13)14) Fiberoptic bronchoscopy has been utilized 
frequently for the diagnosis of such pulmonary 
complications, and many investigators have 
reported its usefulness. 1-12)15)16) Furthermore, 
the value of bronchoscopy in patients with 
AIDS has been confirmed .8- 10) For the diagno-
sis of pulmonary complications in immunocom-
promised patients, bronchoscopy is becoming 
the procedure of first choice among invasive 
techniques such as percutaneous needle biopsy 
and open-lung biopsy. 2-010) 
 The criteria of indication for bronchoscopy 
in immunocompromised patients depend on the 
clinical situation, the underlying disease and 
the bronchoscopic procedure selected. At the 
outset, the following three points should be 
taken into consideration : whether the under-
lying disease is expected to be subsequently 
controlled by a certain type of treatment, 
whether deterioration of the general condition 
is primarily due to pulmonary complications, 
and whether pulmonary infiltrate will interfere 
with any subsequent treatment of the under-
lying disease. Therefore, bronchoscopy is not 
indicated at the end-stage of solid malignant 
tumor. Second, the criteria should fulfill the 
general standards for which bronchoscopy is 
indicated.17) Most of the present patients had 
received chemotherapy and some of them had 
accompanying hypoxemia. Therefore, hypox-
emia and hemorrhagic diathesis are important 
factors to consider among the criteria. Al-
though there is no standard for the level of 
PaO2 adequate for bronchoscopy, many investi-
gators have recommended a PaO2 higher than 
50 to 75 torr regardless of whether supplemen-
tal oxygen is given. 2)4)18) After the procedure 
of combined TBLB and BAL for 12 non-
immunocompromised patients in our study, the
decline in PaO2 ranged from 0.8 to 33.0 torr 
(average 19.6 torr ). Thus, such a decline in 
PaO2 after bronchoscopy should be taken into 
consideration. A platelet count greater than 
50,000 to 70,000/mm3 is desirable for TBLB.2)4) 
In two patients with a platelet count lower 
than 20,000 /mm', we were able to perform 
TBLB with safety after platelet transfusion. 
BAL is applicable to patients on mechanical 
ventilation and those with hemorrhagic diath-
esis. 4)10)11)18 ) Taking the above-mentioned 
points into account together with the choice of 
bronchoscopic procedure, the indication for 
bronchoscopy should be examined carefully in 
each patient. 
 The timing of bronchoscopy is important for 
the early diagnosis and treatment of pulmonary 
complications. When a difinitive diagnosis has 
not been made through non-invasive examina-
tions, it is necessary to rely upon empirical 
treatment. If pulmonary complications are not 
improved by empirical treatment, then the 
point at which bronchoscopy should be per-
formed becomes a critical consideration. It is 
difficult to arrive at a clear conclusion at pres-
ent because of the variety of pulmonary com-
plications. One investigator has proposed that 
invasive examinations should be done one to 
three days after the start of empirical treat-
ment .8 ) Because it is frequently difficult to 
predict pulmonary complications from chest 
radiographs, efforts should be made to find 
them at an early stage using gallium-67 scinti-
graphy and periodic measurements of PaO2.1)9) 
10)'9) When PaO 2 is significantly reduced or 
when diffuse accumulation of gallium is ob-
served in the lung, bronchoscopy should be 
positively undertaken because of its high diag-
nostic sensitivity for diffuse pulmonary le-
sions. 
 Various bronchoscopic procedures such as 
TBLB, BAL, brushing, Asp and bronchial wash-
ing can be selected. The choice of appropriate 
procedure depends on the clinical situation, 
suspected diagnosis and the diagnostic sensitiv-
ity of the selected procedure. As shown in the 
present study, TBLB usually has the highest 
diagnostic sensitivity among the various proce-
dures, and combination of TBLB with other pro-
cedures raises the sensitivity Still. 3 )4 )10 )11)16 )
In the present study, TBLB had a sensitivity of 
55.1%, being especially high for non-infectious 
pulmonary disease. BAL has a high diagnostic 
sensitivity for Pneumocystis carinii pneumo-
nia, mycobacterial disease, cytomegalovirus 
infection, legionnaire's disease and fungal pneu-
monia, and is also useful for pulmonary hemor-
rhage, pulmonary infiltration of hematologic 
malignancy and drug-induced pulmonary dis-
ease.1)4)9)10)12)16-18) Therefore, we think that 
BAL should be employed as actively as TBLB. 
 For the early diagnosis of pulmonary com-
plication, specimens should be treated by rapid 
and sensitive methods. In our two positive fluid 
samples for isolation of CMV, three to four 
weeks was required for the diagnosis. Recently, 
a rapid laboratory method for the detection of 
CMV using a sensitive and specific monoclonal 
antibody against CMV was developed. Using 
this method, the clinical significance of the de-
tection of CMV in pulmonary complications in 
immunocompromised patients has been investi-
gated.7)20) The further development of new and 
rapid methods for diagnosing various pulmo-
nary diseases is thus desirable. 
 Complications from bronchoscopy occurred 
in 9 /50 (18 %) patients, but did not become 
serious. No serious complications have been 
reported in previous studies. 2)4)5) 10)11) Reported 
complications have included pneumothorax, 
hemorrhage, transient increase in temperature, 
worsening of pulmonary infiltrate and hypox-
emia. 1)4)10-12) We think that bronchoscopy is 
a safe diagnostic method for use in immuno-
compromised patients, if such patients are 
carefully selected. 
 Some investigators have doubted the useful-
ness of bronchoscopy, since diagnostic broncho-
scopy does not necessarily prolong patient 
survival.2)5)15)21) In the present study, no pro-
longed survival was noted following diagnostic 
bronchoscopy, reflecting the fact that 80% of 
the diagnosed patients had hematologic malig-
nancy, and that this ratio was greater than 
70% for non-diagnosed patients. 
 In order to evaluate the significance of bron-
choscopy in immunocompromised patients, it 
is necessary not only to equalize the background 
factors of the patients but also to take the 
following points into serious consideration :
indication, timing of bronchoscopy, choice of 
bronchoscopic procedure, treatment of spec-
imens, complications, and effect on patient sur-
vival. After these problems have been solved, 
the usefulness of this technique can be confirm-
ed. 
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